Glucocorticoids and endothelial cell barrier function.

The blood-brain barrier (BBB) is a critical structure that regulates the exchange of substances between blood and the central nervous system. It is composed of specialized endothelial cells that maintain selective permeability. In various neurological conditions, this barrier becomes compromised, leading to increased permeability and potential damage. Glucocorticoids (GCs) are steroid hormones known for their anti-inflammatory and immunosuppressive effects. While their role in systemic inflammation is well established, their impact on BBB integrity remains an area of active investigation. Prior research has shown that GCs can influence endothelial cell behavior through receptor-mediated signaling. However, the precise molecular mechanisms by which GCs affect BBB function are not fully understood. This gap motivated researchers to explore how GCs interact with endothelial cells to regulate barrier properties. The BBB's role in CNS homeostasis makes understanding GC effects particularly relevant for treating neurological disorders.

This review aims to clarify how glucocorticoids influence endothelial cell barrier function, particularly within the context of the blood-brain barrier. The BBB is crucial for maintaining CNS homeostasis, and disruptions can lead to neurological complications. The study focuses on the molecular mechanisms by which GCs exert their effects on endothelial cells. Specifically, it examines how GCs interact with the glucocorticoid receptor (GR) and how this interaction leads to changes in gene expression. The goal is to determine how GCs contribute to the regulation of BBB integrity. Understanding these mechanisms could provide insights into the therapeutic use of GCs for BBB-related disorders. The study also evaluates current therapeutic strategies involving GCs and identifies their limitations. This approach allows for a comprehensive analysis of GCs' role in barrier function.

The authors employed a systematic review approach to synthesize current knowledge on GC effects on endothelial cell barrier function. They analyzed molecular-level mechanisms of GC action, focusing on GR activation and downstream gene regulation. The review included studies that investigated GC effects on BBB-related proteins such as occludin, claudins, and VE-cadherin. The authors examined how ligand-bound GR interacts with GC response elements in gene promoters. They also evaluated how transactivation of target genes influences endothelial cell tightness. The review considered both in vitro and in vivo models of BBB function. Additionally, the authors assessed clinical applications of GCs in BBB-related conditions. The synthesis of this evidence aimed to clarify the role of GCs in maintaining BBB integrity.

The review highlights that GCs improve BBB tightness through GR-mediated gene regulation. Key findings indicate that GCs upregulate genes encoding tight junction proteins like occludin and claudins. These proteins are essential for maintaining endothelial cell barrier function. GCs also influence VE-cadherin expression, which is critical for endothelial cell-cell adhesion. The study shows that GR activation leads to transactivation of target genes, enhancing barrier properties. The results suggest that GCs can modulate BBB permeability in response to inflammatory stimuli. The review also notes that GC effects are dose-dependent and context-specific. Limitations of current GC therapies include potential side effects and variable efficacy across different patient populations.

The authors propose that GCs play a significant role in regulating endothelial cell barrier function, particularly in the BBB. Their findings suggest that GCs enhance barrier integrity through GR-mediated gene expression. The review emphasizes the importance of tight junction proteins like occludin and claudins in this process. The authors also note that GC effects are context-dependent and may vary based on the specific disease state. The study highlights the need for further research to understand the full scope of GC effects on BBB function. The authors suggest that current GC therapies have limitations that require addressing for improved clinical outcomes. They conclude that GCs are a promising therapeutic strategy for BBB-related disorders. However, more research is needed to optimize their use and minimize side effects.